Business
Futura Medical - Notice of Interim Results
Futura Medical - Notice of Interim Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n \n18 August 2023\n Futura Medical plc\n(\"Futura\" or the \"Company\")\nNotice of Interim Results\nFutura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), the pharmaceutical company developing innovative sexual health products, will announce its interim results for the six months ended 30 June 2023 on Monday 18th September 2023.\nThe Company will host a webcast for investors and analysts on the day of the results, which will be made available within the investor centre section of the Company's website.\nA Retail Investor event is scheduled for Tuesday 19th September at 10.00am BST with Investor Meet Company. Retail Investors can register via www.investormeetcompany.com.\n-ENDS-\nFor further information, please contact:\n \nFutura Medical plc\nJames Barder, Chief Executive Officer\nAngela Hildreth, Finance Director and COO\nEmail: [email protected]\nTel: +44 (0) 1483 685 670\nwww.futuramedical.com\n \nNominated Adviser and Sole Broker:\n \nLiberum\nPhil Walker/ Richard Lindley/ Ben Cryer\nTel: +44 (0) 20 3100 2000\n \nFor media enquiries please contact:\n \nOptimum Strategic Communications\nNick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates\nEmail: [email protected]\nTel: +44 (0) 203 882 9621\n \n \nAbout Futura Medical plc\n \nFutura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.\nMED3000, the Company's breakthrough treatment for erectile dysfunction (\"ED\") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of \"Helps you get an erection within 10 minutes\". Eroxon® is available Over the Counter (\"OTC\") without a doctor's prescription. www.eroxon.com.\nMED3000 is being manufactured and commercialised under the brand name Eroxon® in regulatory approved countries and is FDA approved in the US, CE marked in Europe and UKCA marked in the UK and a growing number of countries across the world. Futura has commercial agreements with the likes of Haleon for the US market and Cooper Consumer Health for Europe.\nFutura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange....